KR20220027871A - NF-kB 유도 키나아제의 소분자 억제제 - Google Patents

NF-kB 유도 키나아제의 소분자 억제제 Download PDF

Info

Publication number
KR20220027871A
KR20220027871A KR1020217042635A KR20217042635A KR20220027871A KR 20220027871 A KR20220027871 A KR 20220027871A KR 1020217042635 A KR1020217042635 A KR 1020217042635A KR 20217042635 A KR20217042635 A KR 20217042635A KR 20220027871 A KR20220027871 A KR 20220027871A
Authority
KR
South Korea
Prior art keywords
phenyl
ethynyl
pyrimidin
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217042635A
Other languages
English (en)
Korean (ko)
Inventor
제이. 켄트 바베이
웨닝 차이
웬디 에클스
마이클 디. 핵
에런 티. 헤르만
윌리암 엠. 존스
폴 제이. 크라브주크
케빈 디. 크루터
앨릭 디. 렙세크
다니엘 제이. 피펠
알렉산더 알. 로비라
로날드 엘. 월린
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20220027871A publication Critical patent/KR20220027871A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217042635A 2019-05-31 2020-05-29 NF-kB 유도 키나아제의 소분자 억제제 Pending KR20220027871A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US62/855,144 2019-05-31
US201962907833P 2019-09-30 2019-09-30
US62/907,833 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Publications (1)

Publication Number Publication Date
KR20220027871A true KR20220027871A (ko) 2022-03-08

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042635A Pending KR20220027871A (ko) 2019-05-31 2020-05-29 NF-kB 유도 키나아제의 소분자 억제제

Country Status (37)

Country Link
US (2) US11254673B2 (https=)
EP (2) EP4467199A3 (https=)
JP (2) JP7547387B2 (https=)
KR (1) KR20220027871A (https=)
CN (2) CN118908957A (https=)
AU (1) AU2020282005B2 (https=)
BR (1) BR112021023796A2 (https=)
CL (1) CL2021003142A1 (https=)
CO (1) CO2021017838A2 (https=)
CR (1) CR20210587A (https=)
DK (1) DK3976597T3 (https=)
DO (1) DOP2021000244A (https=)
EC (1) ECSP21093623A (https=)
ES (1) ES2989387T3 (https=)
FI (1) FI3976597T3 (https=)
HR (1) HRP20241352T1 (https=)
HU (1) HUE068694T2 (https=)
IL (1) IL288387B2 (https=)
JO (1) JOP20210318B1 (https=)
LT (1) LT3976597T (https=)
MA (1) MA56038B1 (https=)
MD (1) MD3976597T2 (https=)
MX (1) MX2021014679A (https=)
MY (1) MY205653A (https=)
PE (1) PE20220768A1 (https=)
PH (1) PH12021553011A1 (https=)
PL (1) PL3976597T3 (https=)
PT (1) PT3976597T (https=)
RS (1) RS66105B1 (https=)
SA (1) SA521430960B1 (https=)
SG (1) SG11202112994WA (https=)
SI (1) SI3976597T1 (https=)
SM (1) SMT202400418T1 (https=)
TW (2) TWI850390B (https=)
UA (1) UA130430C2 (https=)
UY (1) UY38721A (https=)
WO (1) WO2020239999A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
US20250304567A1 (en) * 2022-05-11 2025-10-02 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
WO2026029041A1 (ja) * 2024-07-30 2026-02-05 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
EP1773781A2 (en) * 2004-08-03 2007-04-18 Wyeth Indazoles useful in treating cardiovascular diseases
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
JP2011525915A (ja) 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
MX2013010513A (es) * 2011-03-16 2013-10-07 Hoffmann La Roche Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
US9034866B2 (en) 2012-02-17 2015-05-19 Genentech, Inc. Tricyclic compounds and methods of use therefor
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CN105658639A (zh) * 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
JP2016533385A (ja) 2013-08-22 2016-10-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アルキニルアルコール及び使用方法
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
EP3209654B1 (en) 2014-10-23 2018-10-03 Janssen Pharmaceutica N.V. New pyrazole derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
EA033238B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные тиенопиримидина в качестве ингибиторов nik
KR102523405B1 (ko) 2014-10-23 2023-04-18 얀센 파마슈티카 엔.브이. Nik 억제제로서의 신규 피라졸로피리미딘 유도체
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新たな置換されたシアノインドリン誘導体
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ.ホフマン-ラ ロシュ アーゲー 2-アザビシクロ[3.1.0]ヘキサン-3-オン誘導体及び使用方法
CN109863142B (zh) * 2016-08-24 2022-06-10 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
KR102662373B1 (ko) 2017-07-06 2024-04-29 얀센 파마슈티카 엔브이 Nik 억제제로서의 신규 치환 아자인돌린 유도체
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物,其制备方法和用途
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores

Also Published As

Publication number Publication date
ECSP21093623A (es) 2022-01-31
TW202110842A (zh) 2021-03-16
ES2989387T3 (es) 2024-11-26
MA56038A (fr) 2022-04-06
DK3976597T3 (da) 2024-09-09
LT3976597T (lt) 2024-10-10
HUE068694T2 (hu) 2025-01-28
SMT202400418T1 (it) 2024-11-15
TWI850390B (zh) 2024-08-01
US11827634B2 (en) 2023-11-28
DOP2021000244A (es) 2022-04-18
CN118908957A (zh) 2024-11-08
IL288387B2 (en) 2026-01-01
TWI906955B (zh) 2025-12-01
HRP20241352T1 (hr) 2024-12-20
SA521430960B1 (ar) 2024-11-12
JP2022534302A (ja) 2022-07-28
JOP20210318B1 (ar) 2025-10-01
CR20210587A (es) 2022-02-11
US20210300918A1 (en) 2021-09-30
EP4467199A3 (en) 2025-03-05
IL288387A (en) 2022-01-01
IL288387B1 (en) 2025-09-01
CO2021017838A2 (es) 2022-01-17
MX2021014679A (es) 2022-04-06
UA130430C2 (uk) 2026-02-18
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
PT3976597T (pt) 2024-10-22
CA3143350A1 (en) 2020-12-03
CL2021003142A1 (es) 2022-08-19
MA56038B1 (fr) 2024-11-29
JOP20210318A1 (ar) 2023-01-30
SI3976597T1 (sl) 2024-11-29
JP2024167319A (ja) 2024-12-03
US11254673B2 (en) 2022-02-22
BR112021023796A2 (pt) 2022-02-08
PH12021553011A1 (en) 2022-11-07
EP3976597A1 (en) 2022-04-06
WO2020239999A1 (en) 2020-12-03
EP4467199A2 (en) 2024-11-27
JP7547387B2 (ja) 2024-09-09
SG11202112994WA (en) 2021-12-30
MY205653A (en) 2024-11-02
PE20220768A1 (es) 2022-05-16
UY38721A (es) 2020-11-30
FI3976597T3 (fi) 2024-09-25
MD3976597T2 (ro) 2025-01-31
PL3976597T3 (pl) 2024-12-16
CN114222737B (zh) 2024-07-26
US20240199605A1 (en) 2024-06-20
EP3976597B1 (en) 2024-08-28
RS66105B1 (sr) 2024-11-29
AU2020282005B2 (en) 2026-02-12
US20230080834A1 (en) 2023-03-16
TW202517638A (zh) 2025-05-01

Similar Documents

Publication Publication Date Title
JP7547387B2 (ja) NF-κB誘導キナーゼの低分子阻害剤
JP7446236B2 (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアリール-ビピリジンアミン誘導体
JP2018150358A (ja) Tank結合キナーゼインヒビター化合物
KR20130094710A (ko) Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘
JP2011529920A (ja) ピリミジン化合物、組成物及び使用方法
KR20170068503A (ko) 융합된 펜타시클릭 이미다졸 유도체
WO2020223590A1 (en) Modulators of trex1
KR20230069169A (ko) 카제인 키나제 1 델타 조절제
US12617789B2 (en) Small molecular inhibitors of NF-κb inducing kinase
CA3143350C (en) Small molecule inhibitors of nf-kb inducing kinase
HK40119602A (en) Small molecule inhibitors of nf-kb inducing kinase
US20230416256A1 (en) SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
EA045720B1 (ru) НИЗКОМОЛЕКУЛЯРНЫЕ ИНГИБИТОРЫ NF-κB-ИНДУЦИРУЮЩЕЙ КИНАЗЫ
HK40071178A (en) Small molecule inhibitors of nf-kb inducing kinase
HK40071178B (en) Small molecule inhibitors of nf-kb inducing kinase
US20250282785A1 (en) Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
TW202506660A (zh) Mrgprx2拮抗劑及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701